DIAGENS-B's stock soared 15.69% during the morning session, reaching a record high. The stock has shown significant momentum, with gains continuing from recent positive developments.

The surge follows the company's participation in the third phase of the Canton Fair, where it presented its self-developed iMedImage® medical imaging foundation model in the Smart Healthcare zone. The presentation attracted significant attention, with the company's booth crowded with buyers from regions including the Middle East, Southeast Asia, and Europe who showed strong interest in its technology and products.

Additionally, the company's 2025 annual report demonstrated strong performance with a 332% surge in technology licensing revenue, validating the feasibility of its large model commercial loop. DIAGENS-B maintains a dominant position with a 30.6% market share in a policy-driven essential sector, and the endorsement of its iMedImage® foundation model by leading institutions such as Tencent underscores its strategic value as a global AI medical infrastructure service provider.